The Sconi

The U.S. Food and Drug Administration (FDA) has approved a generic version of the abortion drug mifepristone, according to an announcement this week. The manufacturer of the new generic product has stated that its purpose is to "terminate a pregnancy" and that it aims to "normalize abortion."

Wisconsin Right to Life responded to the FDA's decision by expressing concern over what it describes as weakened safety protocols for mifepristone in recent years. The organization noted that requirements such as in-person medical screening, ultrasounds, and follow-up visits were previously in place but have since been relaxed.

According to Wisconsin Right to Life, chemical abortion drugs like mifepristone have a higher complication rate compared to surgical abortions. The group cited risks including severe bleeding, pain, infection, and the potential need for emergency surgery. It also raised concerns about these risks going undetected without doctor supervision.

The FDA commissioner Marty Makary has said that the agency is investigating the safety of mifepristone. In addition, HHS Secretary Robert F. Kennedy Jr. stated that the Biden Administration “twisted the data” regarding the safety profile of the abortion pill.

Heather Weininger, Executive Director of Wisconsin Right to Life, commented on behalf of her organization: “We urge the FDA to, at bare minimum, reinstate the reasonable safety restrictions that existed during President Trump’s first term for mifepristone and its generic counterpart. Whether brand-name or generic, these abortion drugs — without proper medical oversight — will harm women. Women deserve real healthcare, real compassion, and real support — not a pill that ends one life and endangers another.”